News Release

Germline genetic testing after cancer diagnosis – this study is being released to coincide with presentation at the 2023 ASCO Annual Meeting

JAMA

Peer-Reviewed Publication

JAMA Network

About The Study: Among patients diagnosed with cancer in California and Georgia between 2013 and 2019, only 6.8% underwent germline genetic testing. Compared with non-Hispanic white patients, rates of testing were lower among Asian, Black, and Hispanic patients. 

Authors: Allison W. Kurian, M.D., M.Sc., of Stanford University in Stanford, California, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jama.2023.9526)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with presentation at the 2023 ASCO Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.9526?guestAccessKey=25ebf227-5d6d-4d77-8b38-6dcfeef179d3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060523


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.